<a href="https://www.fiercebiotech.com/biotech/servier-inks-265b-buyout-edgewises-muscular-dystrophy-unit-beef-neurology-pipeline" hreflang="en">Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline</a>
Servier has acquired Edgewise Therapeutics' muscular dystrophy unit for $2.6 billion to enhance its neurology pipeline, gaining access to the oral drug candidate sevasemten, which is set to deliver pivotal data for Becker muscular dystrophy this year. The deal allows Edgewise to focus on its cardiovascular assets while providing funding for further development.
Servier's $2.6 billion acquisition of Edgewise's muscular dystrophy unit, specifically for the drug candidate sevasemten, signals a strategic bet on expanding their neurology pipeline with a novel mechanism targeting muscle contraction. This move highlights an opportunity in investing in rare disease therapeutics with unique mechanisms of action, as well as the importance of securing funding for further development of related cardiovascular assets, such as Edgewise’s EDG-7500. This acquisition not only positions Servier to potentially lead in neurology but also underscores the value of robust, diversified pipelines in biotech M&A strategies.